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Sir, Autosomal dominant optic atrophy (DOA) is a common cause
of inherited visual failure affecting at least 1 in 35000 of the
general population (Yu-Wai-Man et al., 2010a). Pathogenic
OPA1 mutations account for about 60% of all cases, causing bi-
lateral, symmetrical optic atrophy secondary to the highly
tissue-speciﬁc loss of one cell type - the retinal ganglion cell
(Lenaers et al., 2009). Although optic nerve degeneration remains
the deﬁning feature of DOA, we recently reported in Brain that
up to 20% of patients with OPA1 mutations will also develop
additional neuromuscular complications including deafness,
ataxia, myopathy, peripheral neuropathy and progressive external
ophthalmoplegia (Yu-Wai-Man et al., 2010b).
In two earlier studies, also published in Brain (Amati-Bonneau
et al., 2008; Hudson et al., 2008), we described for the ﬁrst
time the intriguing association of these syndromal DOA+ variants
with multiple mitochondrial DNA deletions and cytochrome c
oxidase (COX)-negative skeletal muscle ﬁbres (Zeviani, 2008).
Interestingly, these mitochondrial defects were subsequently
identiﬁed in OPA1 patients with pure optic nerve involvement,
but at levels four times lower compared with the DOA+ group
(Yu-Wai-Man et al., 2010b). The involvement of other tissue
types in DOA+ could therefore be a direct consequence of the
greater accumulation of these secondary mitochondrial DNA
abnormalities, the latter potentiating an already compromised
mitochondrial oxidative reserve due to the mutant OPA1 protein.
To determine whether this was the case, we used in vivo phos-
phorus magnetic resonance spectroscopy (
31P-MRS) to speciﬁcally
measure mitochondrial oxidative function in a subgroup of OPA1
patients from our original reports, correlating our ﬁndings with the
histochemical and mitochondrial DNA defects identiﬁed in skeletal
muscle biopsies, and thus extending our previous observations
(Yu-Wai-Man et al., 2010b).
For this
31P-MRS study, we selected 17 patients harbouring
12 different pathogenic OPA1 mutations [mean age=47.7 years,
standard deviation (SD)=10.6 years, range=30.0–65.0 years):
nine patients with isolated optic atrophy and eight patients with
complex neuromuscular phenotypes (Tables 1 and 2). This patient
group was comparedwith 17 newly identiﬁed, age-matched, normal
controls with no evidence of ocular or neuromuscular pathologies
(mean age=48.3 years, SD=8.5 years, range 37.0–63.0 years,
P=0.8457). This study had the relevant institutional ethical approval
and informed consent was obtained in accordance with the
Declaration of Helsinki.
Resting
31P-MRS parameters were within the normal range for
the entire OPA1 group (Table 3). Similarly, OPA1 patients did not
exhibit abnormalities in proton handling at rest (pH), during or
following exercise (maximum proton efﬂux rate). The overall re-
covery of both phosphocreatine (P=0.0218) and adenosine
diphosphate (ADP) (P=0.0274) to basal levels, as measured by
the half time 1/2, was signiﬁcantly delayed in all OPA1 mutational
carriers. Subgroup analysis showed a signiﬁcant difference for pa-
tients with both pure DOA and DOA+phenotypes compared with
controls, but there was no signiﬁcant difference in 1/2 phospho-
creatine and 1/2 ADP between these two disease subgroups
(Fig. 1A and B). The frequency of COX-negative ﬁbres in skeletal
muscle biopsies (mean=1.9%, SD=2.4%, range=0–10.0%,
n=16) did not correlate with either 1/2 phosphocreatine
(Spearman rank correlation coefﬁcient= 0.0310, P=0.9094) or
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P=0.5449) (Fig. 1C and D). The correlation between COX deﬁ-
ciency and both 1/2 phosphocreatine and 1/2 ADP remained
non-signiﬁcant after exclusion of two outlying data points (Fig.
2). For three DOA+ patients (Patients 3, 7 and 16), citrate syn-
thase and mitochondrial respiratory chain enzyme activities were
determined in mitochondrially enriched suspensions obtained from
homogenized muscle specimens (Taylor et al., 2004). All measure-
ments were within the normal assay range.
OPA1 mutations exert a deleterious effect on in vivo mito-
chondrial function, irrespective of mutational subtypes and disease
severity. Our a priori hypothesis was that the additional
Table 1 Clinical features of our OPA1 patient cohort
Patient Age
(years)
Sex FHx Onset
a
(years)
Snellen BCVA Clinical phenotype
Left Right Optic
Atrophy
Deafness Ataxia Myopathy Neuropathy PEO Others
1 50 M + 8 CF CF +
2 58 F + – 20/30 20/30 + + MS-like illness
3 30 M + 5 CF CF + + + + +
4 38 F + 1 CF CF + + + + + + Migraine
5 43 M + 5 20/200 20/200 +
6 59 M + 5 20/200 20/200 +
74 3 M + 1 3 C F C F + + + + +
8 65 M + 5 20/200 20/200 +
96 0 F + 1 6 C F C F +
10 40 F + 15 20/60 20/120 +
11 44 F + 15 20/120 20/200 + + +
12 54 M + 5 CF CF + +
13 43 M 5 20/200 20/200 + + + +
14 54 M + – 20/20 20/30 +
15 39 M + 15 20/200 20/120 +
16 59 M + 5 CF CF + + HSP, Migraine
17 31 M + 11 20/40 20/60 +
aAge of onset of visual failure.
The clinical and molecular characteristics of the eight patients with DOA+ phenotypes have been detailed previously (Yu-Wai-Man et al., 2010b): Patient 2 (Pedigree
UK-6), Patient 3 (Pedigree UK-11), Patient 4 (Pedigree UK-11), Patient 7 (Pedigree UK-12), Patient 11 (Pedigree UK-8), Patient 12 (Pedigree UK-1), Patient 13 (Pedigree
UK-13) and Patient 16 (Pedigree UK-3). BCVA=best corrected visual acuity; CF=counting ﬁngers; F=female; FHx=family history; HSP=hereditary spastic paraparesis;
M=male; MS=multiple sclerosis; PEO=progressive external ophthalmoplegia.
Table 2 OPA1 mutations and mitochondrial abnormalities identiﬁed in skeletal muscle biopsies
Patient OPA1 mutations Skeletal muscle biopsy
cDNA change Location Consequence Domain COX-negative
ﬁbres (%)
Mitochondrial
DNA deletions
1 c.2613+1g4a Intron 25 Splicing defect 0.0 –
2 c.2613+1g4a Intron 25 Splicing defect 1.4 +
3 c.1635C4A Exon 17 p.S545R Dynamin 0.4 +
4 c.1635C4A Exon 17 p.S545R Dynamin N/A N/A
5 c.2708_2711delTTAG Exon 27 p.V903fsX3 GED 0.6 +
6 Exons 1-5b deletion p.M1fsX208 2.0 +
7 c.1294A4G Exon 13 p.I432V GTPase 10.0 +
8 c.2818+5g4a Intron 27 Splicing defect 3.0 +
9 c.2713C4T Exon 27 p.R905X GED 3.0 +
10 c.2713C4T Exon 27 p.R905X GED 0.5 +
11 c.32+1g4a Intron 1 Splicing defect 2.0 +
12 c.1212+3a4t Intron 12 Splicing defect 0.3 +
13 c.1334G4A Exon 14 p.R445H GTPase 3.1 +
14 c.1516+1g4t Intron 15 Splicing defect 1.8 +
15 c.1516+1g4t Intron 15 Splicing defect 0.0 +
16 c.876-878delTGT Exon 9 p.V294fsX667 2.1 +
17 c.876-878delTGT Exon 9 p.V294fsX667 0.1 +
COX=cytochrome c oxidase; GED=GTPase effector domain; GTP=guanosine triphophate; N/A=not available.
e164 | Brain 2011: 134; 1–5 Letter to the EditorFigure 1 Subgroup comparison of post-exercise
31P-MRS parameters between patients with pure DOA (n=9), DOA+ (n=8) and
age-matched normal controls (n=17), for (A) 1/2 phosphocreatine (PCr): *P=0.0434, ** P=0.0014, non-signiﬁcant (NS) at P=0.6406,
and (B) 1/2 adenosine diphosphate (ADP): *P=0.0256, **P=0.0079, NS at P=0.5627. Correlation of in vivo markers of metabolic
recovery with the frequency of COX-negative ﬁbres identiﬁed in skeletal muscle biopsies: (C) 1/2 phosphocreatine: Spearman rank
correlation coefﬁcient=0.0310, P=0.9094, and (D) 1/2 ADP: Spearman rank correlation coefﬁcient=0.1636, P=0.5449. The error
bars represent the standard error of the mean.
Table 3 Resting and post-exercise
31P-MRS measurements for OPA1 patients and controls
Patients (n=17) Controls (n=17) P-value
Mean (95% CI) Mean (95% CI)
Age (years) 47.7 (42.2–53.1) 48.3 (43.9–52.7) 0.8457
Resting
PCr (mM) 30.9 (29.8–32.0) 31.9 (30.9–32.8) 0.1539
Pi (mM) 2.90 (2.40–3.39) 3.02 (2.81–3.24) 0.6279
PCr/Pi ratio 11.6 (9.7–13.5) 10.7 (9.9–11.6) 0.3803
ADP (mM) 9.79 (9.48–10.09) 9.82 (9.39–10.25) 0.9029
pH 7.05 (7.04–7.06) 7.05 (7.03–7.07) 0.7598
Post-exercise
Initial PCr resynthesis rate (mM/min) 11.8 (7.9–15.6) 10.5 (8.5–12.5) 0.5366
1/2 PCr (s) 39.4 (28.0–50.8) 25.9 (22.7–29.1) 0.0218*
1/2 ADP (s) 30.1 (21.3–38.8) 20.2 (17.9–22.4) 0.0274*
Maximum proton efﬂux rate (mmol/l/min) 2.75 (2.09–3.42) 2.55 (2.01–3.09) 0.6157
Phosphorus spectra were acquired from the gastrocnemius and soleus muscles using a 3-T Intera Achieva scanner (Philips, Best, The Netherlands)
during: (i) a 1-minute period of rest; (ii) a 3-minute period of plantar ﬂexion at 25% of the maximum voluntary contraction; and (iii) a 6-minute
recovery period (Trenell et al., 2006; Hollingsworth et al., 2008). Spectral quantiﬁcation was performed with the Java-based magnetic resonance
user interface (jMRUI v.3.0), using AMARES with custom prior knowledge appropriate to skeletal muscle (Naressi et al., 2001). ADP=adenosine
diphosphate; PCr=phosphocreatine; Pi=inorganic phosphate. *Signiﬁcant P-value.
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result of a more pronounced biochemical defect. What are the
reasons therefore for the lack of a signiﬁcant difference in bio-
energetic impairment between patients with pure DOA and DOA+
phenotypes? Our results are statistically robust and consistent for
both phosphocreatine and ADP recovery parameters. It is there-
fore unlikely that the inclusion of additional patients would inﬂu-
ence the outcome of this
31P-MRS study. The level of COX
deﬁciency was determined in quadriceps or tibialis anterior biop-
sies, whereas phosphorus spectral data were acquired from the
gastrocnemius and soleus muscles. It is possible that structural
and functional differences exist between these various muscle
groups, which could have inﬂuenced our measurement parameters
and comparisons. Notwithstanding this caveat, our observations
overall indicate that impaired oxidative phosphorylation is only
part of the problem, and different pathways must be mediating
retinal ganglion cell loss and cellular dysfunction in other organ
systems. It is also intriguing that the same OPA1 mutation can
lead to both isolated optic nerve involvement and a more severe
form of the disease, with the development of neuromuscular com-
plications (Yu-Wai-Man et al., 2010b). Additional factors are
clearly modulating the pathogenic expression of the OPA1 muta-
tion resulting in markedly variable clinical phenotypes. Future stu-
dies are required to determine whether DOA+ is related to other
pathological consequences triggered by the greater accumulation
of these mitochondrial DNA deletions; such as the induction of
mitochondrial proliferation, which is known to have a
pro-apoptotic effect (Aure et al., 2006; Yu-Wai-Man et al.,
2010c), or other unrelated mechanisms linked with mitochondrial
network instability, OPA1 being a critical pro-fusion protein
(Lenaers et al., 2009).
Our
31P-MRS study supports an earlier report of impaired
in vivo mitochondrial function in six affected individuals from
two families, segregating isolated optic neuropathy and the
c.2708_2711del(TTAG) deletion (p.V903fsX3) (Lodi et al., 2004).
We have extended this observation to 11 additional pathogenic
OPA1 mutations, including for the ﬁrst time eight patients with
DOA+ phenotypes. Previous
31P-MRS studies have also conﬁrmed
a respiratory chain complex defect in Leber hereditary optic neur-
opathy (LHON), the classic paradigm of a primary mitochondrial
optic neuropathy (Yu-Wai-Man et al., 2009). There seemed to
be a mutational hierarchy; the m.11778G4A LHON mutation
exhibiting the most pronounced effect on mitochondrial ATP
synthesis, followed by m.14484T4C and m.3460G4A (Lodi
et al., 1997, 2002). The latter only led to a subtle metabolic
deﬁcit, highlighting the vulnerability of retinal ganglion cells to
even mild energetic imbalances. Given the pathological similarity
shared by LHON and DOA, it is likely that the bioenergetic defect
revealed by
31P-MRS is contributing to selective retinal ganglion
cell loss and visual failure in both disorders.
In three DOA+ patients, biochemical studies performed on
skeletal muscle mitochondrial fractions were normal, despite the
fact that both their 1/2 phosphocreatine and 1/2 ADP measure-
ments exceeded the upper 95% control values. These ﬁndings
suggest that
31P-MRS could be a useful diagnostic adjunct in pa-
tients with suspected mitochondrial disease, when histochemistry
and in vitro biochemical studies are inconclusive. Furthermore,
mitochondrial oxidative physiology can be inferred both at rest
and crucially following a period of exercise, the post-recovery kin-
etics being particularly sensitive in detecting a tissue’s capacity to
respond to energy demands (Barbiroli et al., 1998).
There is a complex, and still poorly deﬁned, interplay between
the multiple cellular functions regulated by the OPA1 protein.
However, irrespective of the combination of factors involved, the
ultimate loss of mitochondrial membrane potential and the release
of cytochrome c molecules are likely to be key ﬁnal common
events triggering apoptotic cell death. Unravelling these intricately
linked mechanisms will hopefully contribute to the long-term goal
of developing therapeutic interventions, not only for DOA, but
also for other mitochondrial optic neuropathies.
Figure 2 Correlation of in vivo markers of metabolic recovery with the frequency of COX-negative ﬁbres identiﬁed in skeletal muscle
biopsies, after exclusion of two outlying data points: (A) 1/2 phosphocreatine (PCr): Spearman rank correlation coefﬁcient=0.1718,
P=0.5570, and (B) 1/2 ADP: Spearman rank correlation coefﬁcient=0.1079, P=0.7134.
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